



Press Release

NEUWAY Pharma Extends First Round Financing to € 5.85 Million

Bonn, October 22, 2015 - NEUWAY Pharma announced today the successful closing of a € 3.15 Mio Series A Extension financing round to a total of € 5.85 Million. The lead investor Wellington Partners provided € 2.0 Million of the acquired funds. Life Science Inkubator, Kreditanstalt für Wiederaufbau (KfW) and several private shareholders also participated in the financing round.

Besides the development of the proprietary CNS drug delivery platform, the financial resources allow NEUWAY the production of clinical trial material according to GMP. "I am pleased about the great confidence the investors and shareholders have in our company. Continued funding will accelerate the development of our technology and we will soon be able to start testing with GMP material", says Dr. Heiko Manninga, co-founder and Managing Director of NEUWAY.

"Solid financial backing will enable NEUWAY to transform itself from a research company to a development company", comments Dr. Rainer Strohmenger, General Partner at Wellington Partners, " We believe in broad applicability of the CNS drug delivery platform of NEUWAY and we will do everything to support the company in their further development."

**About NEUWAY Pharma**

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

NEUWAY had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, Germany, where it had been incubated for the last 4 years and supported with approx. € 2.3 million in research funding by the Federal Ministry of Education and Research. The company closed a series A financing round in May 2014 with a volume of € 2.7 million provided by a syndicate led by Wellington Partners.

Further information

NEUWAY Pharma GmbH:

Press Contact:

Christine Kuhn, +49-(0)228-522198-15, kuhn@neuway.de

www.neuway-pharma.de